Relative to existing immunotherapy related signatures, the pan-cancer STMN2.SIG achieved markedly higher AUC values in RCC patients, highlighting its superior predictive capacity for immunotherapy response in RCC patients (Supplementary Figure S7B). This evidence concerns the gene STMN2 and cancer.